{"id":31132,"date":"2022-05-31T22:02:14","date_gmt":"2022-05-31T22:02:14","guid":{"rendered":"https:\/\/harchi90.com\/once-again-the-fda-is-delaying-biomarins-hemophilia-a-quest-as-gene-therapy-frets-simmer-endpoints-news\/"},"modified":"2022-05-31T22:02:14","modified_gmt":"2022-05-31T22:02:14","slug":"once-again-the-fda-is-delaying-biomarins-hemophilia-a-quest-as-gene-therapy-frets-simmer-endpoints-news","status":"publish","type":"post","link":"https:\/\/harchi90.com\/once-again-the-fda-is-delaying-biomarins-hemophilia-a-quest-as-gene-therapy-frets-simmer-endpoints-news\/","title":{"rendered":"Once again, the FDA is delaying BioMarin&#8217;s hemophilia A quest as gene therapy frets simmer &#8211; Endpoints News"},"content":{"rendered":"<div>\n<p>Count GSK in for the pneumococcal vaccine race.<\/p>\n<p>The British pharma is wagering $ 2.1 billion in cash &#8211; plus up to $ 1.2 billion in milestones &#8211; to buy out Affinivax and its 24-valent pneumococcal vaccine candidate, now in Phase II, as well as the technology that gave birth to the shot.<\/p>\n<p>&#8220;The proposed acquisition further strengthens our vaccines R&#038;D pipeline, provides access to a new, potentially disruptive technology, and broadens GSK&#8217;s existing scientific footprint in the Boston area,&#8221; said outgoing R&#038;D chief Hal Barron, who&#8217;s leaving in August to run the cell rejuvenation startup Altos Labs.<\/p>\n<div class=\"epn_limit\">\n    <\/p>\n<h3>Keep reading Endpoints with a free subscription<\/h3>\n<p>  Unlock this story instantly and join 142,900+ biopharma pros reading Endpoints daily &#8211; and it&#8217;s free. <\/p>\n<p>\n        <button type=\"button\" class=\"epn_ux_button epn_more epn_gate_sign_up_button\" data-toggle=\"modal\" data-target=\"#epn_subscribe_modal\">SIGN UP<\/button><br \/>\n        <button type=\"button\" class=\"epn_ux_button epn_more epn_gate_log_in_button\" data-toggle=\"modal\" data-target=\"#epn_sign_in_modal\">LOG IN<\/button>\n    <\/p>\n<\/div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Count GSK in for the pneumococcal vaccine race. The British pharma is wagering $ 2.1 billion in cash &#8211; plus up to $ 1.2 billion in milestones &#8211; to buy out Affinivax and its 24-valent pneumococcal vaccine candidate, now in Phase II, as well as the technology that gave birth to the shot. &#8220;The proposed &hellip;<\/p>\n<p class=\"read-more\"> <a class=\"\" href=\"https:\/\/harchi90.com\/once-again-the-fda-is-delaying-biomarins-hemophilia-a-quest-as-gene-therapy-frets-simmer-endpoints-news\/\"> <span class=\"screen-reader-text\">Once again, the FDA is delaying BioMarin&#8217;s hemophilia A quest as gene therapy frets simmer &#8211; Endpoints News<\/span> Read More &raquo;<\/a><\/p>\n","protected":false},"author":1,"featured_media":31133,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","spay_email":"","jetpack_publicize_message":"","jetpack_is_tweetstorm":false,"jetpack_publicize_feature_enabled":true},"categories":[8],"tags":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/endpts.com\/wp-content\/uploads\/2020\/08\/Jean-Jacques-Bienaime-BioMarin-tile-YouTube-scaled.jpg?ssl=1","jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"fifu_image_url":"https:\/\/endpts.com\/wp-content\/uploads\/2020\/08\/Jean-Jacques-Bienaime-BioMarin-tile-YouTube-scaled.jpg","_links":{"self":[{"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/posts\/31132"}],"collection":[{"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/comments?post=31132"}],"version-history":[{"count":0,"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/posts\/31132\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/media\/31133"}],"wp:attachment":[{"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/media?parent=31132"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/categories?post=31132"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/tags?post=31132"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}